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We have shown that immunization with soluble recombinant chlamydial protease-like
activity factor (rCPAF) and a T helper 1 type adjuvant can induce signiﬁcantly enhanced
bacterial clearance and protection against Chlamydia-induced pathological sequelae in the
genital tract. In this study, we investigated the use of bone marrow derived dendritic
cells (BMDCs) pulsed ex vivo with rCPAF+CpG in an adoptive subcutaneous immu-
nization for the ability to induce protective immunity against genital chlamydial infection.
We found that BMDCs pulsed with rCPAF+CpG efﬁciently up-regulated the expression
of activation markers CD86, CD80, CD40, and major histocompatibility complex class II
(MHC II), and secreted interleukin-12, but not IL -10 and IL -4. Mice adoptively immunized
with rCPAF+CpG-pulsed BMDCs or UV-EB+CpG-pulsed BMDCs produced elevated lev-
els of antigen-speciﬁc IFN-γ and enhanced IgG1 and IgG2a antibodies. Moreover, mice
immunized with rCPAF+CpG-pulsed BMDCs or UV-EB+CpG-pulsed BMDCs exhibited
signiﬁcantly reduced genital Chlamydia shedding, accelerated resolution of infection, and
reduced oviduct pathology when compared to infected mock-immunized animals. These
results suggest that adoptive subcutaneous immunization with ex vivo rCPAF-pulsed
BMDCs is an effective approach, comparable to that induced by UV-EB–BMDCs, for
inducing robust anti-Chlamydia immunity.
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INTRODUCTION
Chlamydia trachomatis is an obligate intracellular Gram-negative
bacteriumthatistheleadingcauseofbacterialsexuallytransmitted
disease worldwide (Morrison and Caldwell, 2002; Gottlieb et al.,
2010). Development of an effective vaccine has been suggested to
be the most promising and effective strategy to prevent this dis-
ease (Rank, 1999; Brunham and Rey-Ladino, 2005; Hafner and
McNeilly, 2008); however, an efﬁcacious anti-chlamydial vaccine
has yet to be licensed for human use. Current Chlamydia vaccine
research efforts in general are focused mainly on the develop-
ment of recombinant subunit vaccines including, but not limited
to, the major outer membrane protein (MOMP; Pal et al., 2005;
Kari et al., 2009; Sun et al., 2009), other outer membrane pro-
teins(OMPs;Olsenetal.,2010),polymorphicmembraneproteins
(PMPs; Yu et al., 2009; Eko et al., 2011), a immunogenic plasmid
protein (PGP3; Chen et al., 2010), and the protease-like activity
factor (CPAF; Li et al.,2007,2008; Murthy et al.,2007).
Some of these recombinant subunit candidates induce
enhanced chlamydial clearance and reduced upper genital tract
pathologies,butnoneof theminducesterilizingprotectiveimmu-
nity. For example, we have shown previously that immunization
withsolublerecombinant(r)CPAFinducessigniﬁcantlyenhanced
genital chlamydial clearance (Li et al.,2010),reduction of oviduct
pathology (Murthy et al., 2007), and preservation of fertility fol-
lowing primary and/or repeated chlamydial challenge (Murthy
etal.,2011).Thelackof sterilizingimmunitysuggestedthateither
a single subunit is inadequate as a vaccine, or the need for a
more effective delivery system to optimize the effect of a single
subunit candidate. Dendritic cells (DCs) are professional anti-
gen presenting cells (APCs) and key players in determining the
type and quality of T cell immune response. Immature DCs in
the peripheral tissue are highly active in phagocytosis and pro-
cessing microbial antigens and undergo a maturation process as
they migrate to draining lymphoid tissues. The utility of ex vivo
antigen-pulsedDCsasaneffectiveinducerof protectiveimmunity
has been extensively studied for tumor immunity and infectious
agents (Svensson et al.,1997; Siegemund andAlber,2008). To this
end, ex vivo Chlamydia-pulsed dentritic cell (DC) transfer has
been shown to induce robust protective immunity comparable to
that induced by a live Chlamydia infection (Su et al.,1998).
In this study, we evaluated whether subcutaneous immu-
nization with DCs pulsed ex vivo with soluble (r) chlamydial
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protease-like activity factor (rCPAF) would elicit an augmented
immune response to induce sterilizing immunity against sub-
sequent primary genital C. muridarum challenge. Bone marrow
derived dendritic cells (BMDCs) pulsed ex vivo with rCPAF, with
CpG as an adjuvant, displayed enhanced expression of activatory
surface markers and secreted a high level of IL-12, an inducer
of T helper 1 (Th1) type immunity. Mice immunized subcu-
taneously with the rCPAF-pulsed BMDCs induced a high level
of antigen-speciﬁc IFN-γ and anti-chlamydial antibody produc-
tion, and induced signiﬁcant protective immunity against genital
Chlamydia infection.
MATERIALS AND METHODS
RECOMBINANT PROTEINS, CHLAMYDIA, AND MICE
The recombinant chlamydial proteins were puriﬁed as previously
described (Li et al., 2008). Brieﬂy, rCPAF constructs from C. tra-
chomatis L2 genome with a 6X-Histidine tag (His) were cloned
into pBAD vectors (Dong et al., 2004). The fusion proteins were
expressed in Escherichia coli with l-arabinose as an inducer and
extracted by bacterial lysis using sonication in a Triton X-100 lysis
buffer.Ni–NTAagarosebeads(Amersham,NJ,USA)wereusedfor
puriﬁcation of rCPAF. The fusion protein was concentrated using
CentriplusYM-10 tubes (Millipore,MA,USA),suspended in PBS
with proteinase inhibitor cocktail (Roche, CA, USA), aliquoted,
and then stored at −20˚C. The purity of rCPAF was evaluated by
SDS-polyacrylamidegelelectrophoresisandbyWesternblotusing
antigen-speciﬁc murine antibodies. CpG (TCCATGACGTTCCT-
GACGTT) was obtained from Sigma Genosys (St. Louis, MO,
USA).
Chlamydia muridarum was grown on conﬂuent HeLa cell
monolayers. Cells were lysed using a sonicator (Fisher Scientiﬁc,
PA, USA) and elementary bodies (EBs) puriﬁed on Renografﬁn
gradients as described previously (Li et al.,2007).Aliquots of bac-
teria were stored at -70˚C in sucrose–phosphate–glutamine (SPG)
buffer.
Four to six week-old, female BALB/c mice were obtained from
Charles River Laboratory (Bar Harbor, ME, USA). Mice were
housed and bred at the University of Texas at San Antonio and
providedfoodandwateradlibitum.Animalcareandexperimental
procedures were performed in compliance with the Institutional
Animal Care and Use Committee (IACUC) guidelines.
DENDRITIC CELL ISOLATION AND STIMULATION
Bone marrow-derived dendritic cells were prepared as described
(Su et al., 1998). In brief, 4–6week-old female BALB/c mice were
sacriﬁced and bone marrow was collected from both tibias and
femurs. Erythrocytes were lysed by ammonium chloride treat-
ment, and the cells immediately resuspended in Hank’s Gelatin
Buffer. After washing the cells with HBSS buffer, BMDCs were
cultured in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) sup-
plementwith10%FBS,4mMl-glutamine,10U/mlpenicillinand
streptomycin, 0.5mM 2-mercaptoethanol, 10ng/ml each of IL-
4, and granulocyte–macrophage-colony stimulating factor (GM-
CSF). On day 3, fresh 10ng/ml each of IL-4 and GM-CSF was
added to the culture. After 6days of incubation, loosely adherent
and non-adherent cells were harvested, washed, and resuspended
in Hanks buffered salt solution (Gibco). A 2.3ml Opti-Prep
concentrate (Sigma) was added to 9.7ml buffer [0.88% (wt/vol)
NaCl,1mM EDTA,0.5% (wt/vol) bovine serum albumin,10mM
HEPES, pH 7.4, ﬁlter sterilized]. The cell suspension was gently
layered on the top of 6ml of the Opti-Prep mixture and cen-
trifuged at 600×g for 5min. The interface was collected and
washed, and the cells cultured for another 1–2days for use and
the enriched DCs (over 85% purity as determined by CD11c
surface expression using ﬂow cytomtery) were used for experi-
ments. For CpG, rCPAF+CpG, UV-EB+CpG stimulation, DCs
were plated for 4h in 24-well plates at 106 cells/ml in the pres-
ence of either 10μg/ml rCPAF or UV-EB (at an MOI of 10) plus
30μg/ml CpG, or with medium or 30ug/ml CpG alone; the cells
were than washed and incubated for 24h. Cell supernatants were
collected and stored at −70˚C for cytokine proﬁling. Analyses for
IL-12, IL-10, and IL-4 in the supernatant were carried out by
ELISA.
FLUORESCENT ANTIBODY STAINING AND FLOW CYTOMETRY
Dendritic cells alone or DCs pulsed with different antigens were
stained with FITC, phycoerythrin, or APC-conjugated antibodies
(CD80, CD86, CD40, MHC II, and CD11c). Staining was done in
PBScontaining5%FCSonicefor20min,washedthreetimeswith
PBS, and ﬂow cytometry analysis was performed with an LSR II
instrument (BD Biosciences).
ANTIGEN-SPECIFIC CD4+ T CELL RESPONSES
Fourteen days after mice had been previously challenged and
resolved Chlamydia genital tract infection, spleens (3–5) were
removed,andsplenocyteslayeredoveradensitygradienttocollect
mononuclear cells. CD4+ T cell populations were isolated using
negativeselectionmagneticparticles(StemCellTechnologies,BC,
Canada) and the purity was determined to be at least >90–95%
of CD4+ T cells by ﬂow cytometry using an PE-conjugated anti-
CD4monoclonalantibody(BDBiosciences,CA,USA).Aseparate
pool of naïve splenocytes was prepared from PBS (mock) immu-
nized animals and treated with mitomycin-C (25μg/107 cells) for
20min and used as a source of APCs. The puriﬁed CD4+ Tc e l l s
(5×105 cells/well) were cultured with APCs (105 cells/well) at a
5:1 ratio in 0.2ml and stimulated for 72h in vitro with rCPAF
(2μg/well),UV-inactivatedC.muridarum [106 inclusionforming
units(IFU)/well,10MOI],theunrelatedantigenhenegglysozyme
(HEL,2μg/well),ormediumaloneincultureplates.Supernatants
from the culture wells were analyzed for IFN-γ, IL-10, and IL-4
production using BD OptELISA kits (BD Pharmingen, NJ, USA)
as described previously.
ADOPTIVE IMMUNIZATION AND CHLAMYDIA CHALLENGE
Dendritic cells were incubated with IMDM medium, rCPAF
(10μg/ml), or UV-EB (ratio of 1:10) plus 30μg/ml CpG at 37˚C
for 4h, washed, and incubated in IMDM-10 containing GM-CSF
for 24h. Then rCPAF+CpG or UV-EB+CpG-pulsed DCs were
collected and injected subcutaneously into mice at a concentra-
tion of 1×106 cells/mouse in 0.1ml PBS twice at days 0 and
1 4 .S e v e nd a y sb e f o r eChlamydia challenge, mice were treated
with 2.5mg/mouse Depo-provera (Pﬁzer) to synchronize estrous.
One month following the ﬁnal vaccination, mice were challenged
intravaginally with 5×104 CFU of C. muridarum in 5μl of SPG
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buffer. Protection was assessed by quantifying the number of IFU
recovered from vaginal swabs obtained on the indicated days after
challenge. Entire genital tracts were removed from mice at day
80 after challenge and examined for the presence of hydrosalpinx,
gross pathology evaluation, and histopathology.
DETECTION OF ISOTYPE ANTIBODY LEVELS BY ELISA
Ten days after the ﬁnal immunization, sera from the animals
were analyzed by ELISA as described previously (Li et al., 2007).
Microtiter plates were coated overnight with rCPAF (5μg/ml)
in sodium bicarbonate buffer (pH 9.5). Serial dilutions of sera
were added to wells, followed by either goat anti-mouse IgG1 or
IgG2a conjugated to alkaline phosphatase (Southern Biotechnol-
ogyAssociates,AL,USA).Afterwashing,p-nitrophenylphosphate
substrate(Sigma,MO,USA)wasaddedforcolordevelopmentand
the absorbance at 405nm measured using a μQuant microplate
reader (Biotek Instruments, VT, USA). Reciprocal serum dilu-
tions corresponding to 50% maximal binding were used to obtain
titers.
VAGINAL C. MURIDARUM CHALLENGE AND DETERMINATION OF
BACTERIAL SHEDDING
One month following the ﬁnal vaccination, animals were chal-
lengedintravaginally(i.vag.)with5×104 IFU.Vaginalchlamydial
shedding was determined on the indicated days for a period of
30days following challenge, by swabbing the vaginas of infected
mice and incubating the swabbed material on HeLa cell monolay-
ers grown on glass cover slips in 24-well plates. Cells were ﬁxed
with 2% paraformaldehyde and stained using a genus-speciﬁc
rabbit monoclonal antibody and FITC labeled goat anti-rabbit
secondaryantibody.Thenumberof inclusionswascountedunder
a Zeiss Axioskop microscope, in 10 random mid-line ﬁelds for
days 3–12 and over the entire cover slips for later time points. The
mean±SEM of recovered chlamydial IFU per group of mice is
reported.
ASSESSMENT OF GROSS PATHOLOGY IN THE UPPER GENITAL TRACT
AND HISTOPATHOLOGY
Mice were euthanized at day 80 post-challenge, genital tracts col-
lected, and the presence of gross hydrosalpinx was noted. The
tissues were then photographed from a ﬁxed distance at 6mega-
pixels using a Fuji F10 camera. Images were stored at high resolu-
tionandprintedonsheets(A4size)ofpaper.Dilatationofoviducts
was scored as follows: the cross-sectional diameter of the oviducts
was measured for the largest oviduct loop and the measurements
forindividualmiceandmean±SEforeachgroupwasdetermined
as described previously. Genital tracts also were examined for the
presence of hydrosalpinx,then ﬁxed in 10% neutral formalin,and
embedded into parafﬁn blocks. Serial horizontal sections (5μm)
were prepared and stained using hematoxylin and eosin (H&E).
StainedsectionswerevisualizedusingaZeissAxioskopmicroscope
and scored in blinded fashion as described previously. Cellular
parameters[polymorphonuclearcells(PMNs),mononuclear,and
plasma cells] were individually scored as follows: 0, no signiﬁcant
presence of inﬁltration,1,presence of inﬁltration at a single focus,
2, presence at two to four foci, 3, presence at more than four foci,
or 4,conﬂuent inﬁltration. Results are expressed as mean±SD of
scores from all animals in a group.
STATISTICAL ANALYSES
Sigma Stat (Systat Software Inc., San Jose, CA, USA) was used to
performalltestsof signiﬁcance.Student’st-testwasusedforcom-
parisons between two groups and analysis of variance (ANOVA)
between multiple groups for vaginal chlamydial shedding and
dilatation of hydrosalpinx. A chi-square test was used to compare
theincidenceof hydrosalpinx.p ≤0.05wasconsideredstatistically
signiﬁcant. Microscopic oviduct pathology and histopathology
scores were compared using ANOVA on ranks. All experiments
were repeated at least twice, and each experiment was analyzed
independently.Insomeexperiments,whereoviductdiameterdata
are shown as a composite of two experiments, the indicated sig-
niﬁcant difference holds true when the experiments are analyzed
individually.
RESULTS
BMDCs PULSED WITH rCPAF PLUS CpG UP-REGULATED THE
EXPRESSION OF SURFACE ACTIVATION MARKERS
Bonemarrow-derivedDCsweregeneratedandpulsedexvivo with
IMDM alone, CpG, rCPAF+CpG, or UV-EB+CpG. After 24h
incubation, BMDCs were collected, and then examined by FACS
analysisforexpressionof surfaceactivationmarkersCD86,CD40,
CD80, and MHC II. The purity of CD11c+ BMDCs was 85.3%
(Figure 1A, right panel), which was consistent with previous
reports of 82–86% (Eaton et al., 2006). Only 0.6% of the BMDCs
stained with an isotype control antibody (Figure 1A, left panel)
conﬁrming the speciﬁcity of the anti-CD11c antibody. As shown
in Figure 1B, BMDCs incubated with IMDM displayed a base-
line expression of CD86 (64.8%), CD80 (48%), CD40 (27.8%),
and MHC II (65.2%) and, as expected, the isotype control anti-
body stained cells displayed minimal expression of each marker.
BMDCsincubatedwithCpGalonedisplayedenhancedexpression
of CD86 (83.4%), CD80 (69.0%), CD40 (80.4%), and MHC II
(90.1%).BMDCsincubatedwithrCPAF+CpGorUV-EB+CpG
also displayed enhanced expression of CD86 (80.9 or 79.6%),
CD80 (70.3 or 61.3%), CD40 (80.1 or 79.2%), and MHC II (89.1
or 86.1%). These results suggest that BMDCs pulsed ex vivo with
the antigens, with CpG as an adjuvant, develop into a mature DC
phenotype.
BMDCs PULSED WITH rCPAF PLUS CpG PRODUCE ELEVATED LEVELS OF
IL-12
Dendritic cells play an essential role in priming the differentia-
tion of naïve T cells to Th1, Th2, or Th17 (Perry et al., 1997;
Allam et al., 2009). Interleukin-12 is an especially potent inducer
of Th1immunity(Huangetal.,1999;LuandZhong,1999),which
has been shown to play a dominant role in protection against
genital chlamydial infection (Zhang et al., 1999). Therefore, we
evaluated the production of IL-12 by BMDCs pulsed ex vivo with
CpG, rCPAF+CpG, UV-EB+CpG, or medium after incubation
for 24h. The supernatants were assayed by ELISA for IL-12,IL-10,
and IL-4 (Figure2).All BMDCs displayed signiﬁcantly (p ≤0.01)
increased levels of IL-12, but not IL-10 or IL-4, when compared
to BMDCs pulsed with medium alone. The levels of IL-12 pro-
duction were enhanced comparably between the BMDCs treated
with CpG (1435±376pg/ml), rCPAF+CpG (1028±63pg/ml),
or UV-EB+CpG (1240±80pg/ml). These results suggest that
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FIGURE 1 | Surface activation marker expression by BMDCs using FACS
analysis. (A)The purity of BMDCs was determined by anti-CD11c antibody
(B) Surface marker expression on BMDCs. Bone marrow-derived DCs were
pulsed, washed, and cultured overnight as described in Section “Materials
and Methods.” Harvested DCs were surface stained for antibodies against
CD86, CD80, CD40, and MHC II.The percentages of positive cells are
indicated. One experiment from two independent experiments with similar
results is shown.
rCPAF+CpG-pulsed BMDCs are capable of priming a robust
Th1 response.
BMDCs PULSED WITH rCPAF PLUS CpG RESPOND TO
INFECTION-SENSITIZED CD4+ T CELLS
WealsoevaluatedwhetherBMDCspulsedexvivowithrCPAF,UV-
EB, or an unrelated antigen HEL were capable of processing and
presenting antigens to elicit an antigen-speciﬁc IFN-γ response
fromChlamydia-speciﬁcCD4+ Tcells(Figure3).BMDCspulsed
with rCPAF+CpG and UV-EB+CpG induced Chlamydia-
speciﬁc CD4+ T cells to produce signiﬁcantly (p ≤0.01) higher
levels of IFN-γ (1194±309.5 and 8298±586pg/ml,respectively)
compared to HEL pulsed BMDCs (39±12.5pg/ml).As expected,
naïve CD4+ T cells displayed minimal IFN-γ production upon
culturing with BMDCs pulsed with the different antigens. These
results suggest that BMDCs pulsed ex vivo with rCPAF+CpG
process and present CPAF epitopes to CD4+ T cells,leading to the
production of high levels of IFN-γ in an antigen-speciﬁc fashion.
MICE IMMUNIZED SUBCUTANEOUSLY WITH EX VIVO
ANTIGEN-PULSED BMDCS DISPLAY ROBUST ANTIGEN-SPECIFIC
CYTOKINE AND ANTIBODY RESPONSES
Theinductionofantigen-speciﬁccytokineandantibodyresponses
were evaluated following immunization with BMDCs pulsed ex
vivo with rCPAF+CpG, UV-EB+CpG, or HEL+CpG. Four-
teen days following initial immunization, splenic CD4+ Tc e l l s
were puriﬁed, cultured with mitomycin-C treated APCs, stim-
ulated in vitro with rCPAF or UV-EB, and IFN-γ produc-
tion into the supernatant measured by ELISA. As shown in
Figure 4A, mice vaccinated with rCPAF+CpG-BMDCs exhib-
ited signiﬁcantly (p ≤0.05) greater rCPAF-speciﬁc IFN-γ pro-
duction (1859±216pg/ml) than mice immunized with BMDCs
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FIGURE 2 | BMDCs pulsed ex vivo with CpG, rCPAF+CpG,
UV-EB+CpG secrete IL-12. BMDCs were cultured in medium alone as a
control or following pulsing with CpG, rCPAF+CpG, UV-EB+CpG for 4h;
the cells were than washed and incubated for 24h. Culture supernatants
were collected and assayed by ELISA for IL -12, IL -10, and IL -4.The results
are one of two independent experiments with similar results. (∗)
Statistically signiﬁcant differences (p <0.01; ANOVA) between the indicated
group and medium-pulsed BMDC are shown.
FIGURE 3 | Infection-sensitized CD4
+T cells secrete IFN-γ in response
to BMDCs pulsed with rCPAF+CpG or UV-EB+CpG. CD4
+ T cells were
collected from naïve mice or those mice (n=3) that had resolved a
Chlamydia genital infection. Puriﬁed CD4
+ T cells were incubated in the
presence of unpulsed BMDC, and BMDC pulsed with HEL+CpG,
rCPAF+CpG, or UV-EB+CpG for 72h, and supernatants was collected.
IFN-γ in supernatants was measured by ELISA. All experiment were
performed in triplicate and repeated on two separate occasions with similar
results.The results represent the mean±SEM from one representative
experiment. (∗) Statistically signiﬁcant differences (p <0.01; ANOVA)
between the indicated group and HEL+CpG-pulsed BMDC are shown.
pulsed with UV-EB+CpG or HEL+CpG. As expected, puri-
ﬁed CD4+ T cells from animals vaccinated with BMDCs pulsed
with UV-EB exhibited the greatest IFN-γ production upon stim-
ulation with UV-EB (1953±119pg/ml). Puriﬁed CD4+ Tc e l l s
from animals immunized with BMDCs pulsed with HEL+CpG
(mock immunized) displayed minimal IFN-γ production upon
stimulationwithanychlamydialantigen,indicatingthespeciﬁcity
ofthemeasuredcytokineresponses.TheseresultsindicateBMDCs
FIGURE 4 | Immune response following subcutaneous vaccination
using BMDCs pulsed with HEL+CpG, rCPAF+CpG, UV-EB+CpG.
(A) Induction of antigen-speciﬁc IFN-γ. Groups (three mice per group) were
immunized s.c. on day 0 with BMDCs pulsed with HEL+CpG,
rCPAF+CpG, or UV-EB+CpG. Fourteen days following initial
immunization, splenic CD4
+ T cells were puriﬁed, cultured with
mitomycin-C treated APCs, stimulated in vitro with rCPAF or UV-EB, and
IFN-γ production into the supernatant measured by ELISA.The
mean±SEM per group is shown. Signiﬁcant differences (p≤0.05; ANOVA)
between the (∗)C P A F+CpG group and BMDCs pulsed with HEL+CpG or
UV-EB+CpG group, (∗∗) between the UV-EB+CpG group and BMDCs
pulsed with HEL+CpG, or rCPAF+CpG group are shown. (B)The level of
antigen-speciﬁc antibody. Groups (six mice per group) were immunized s.c.
on day 0 with BMDCs pulsed with HEL+CpG, rCPAF+CpG, UV-EB+CpG,
and booster immunizations were given on day 14.The serum CPAF-speciﬁc
and UV-EB-speciﬁc antibodies were measured 14days after the last booster
immunization, and the mean±SEM per group of the reciprocal titer
corresponding to the 50% maximal binding is shown.The results are
representative of two individual experiments.
pulsed with rCPAF+CpG may elicit robust induction of antigen-
speciﬁc IFN-γ production in vivo.
The serum antibody responses against rCPAF and UV-EB
were measured 14days after the last booster immunization. As
shown in Figure 4B, animals vaccinated with BMDCs pulsed
with rCPAF+CpG displayed elevated levels of anti-rCPAF IgG1
(416±13.8) and IgG2a (639±95.1) antibody. As expected,
animals immunized with BMDCs pulsed with UV-EB+CpG
exhibited high levels of anti-UV-EB IgG1 (858±136.3) and
IgG2a(2274±111.5)antibody.AnimalsimmunizedwithBMDCs
pulsed with HEL+CpG (mock immunized) exhibited minimal
anti-rCPAF and anti-UV-EB antibodies. Collectively,mice immu-
nized with BMDCs pulsed with rCPAF displayed elevated levels
of antigen-speciﬁc IFN-γ production and increased levels of anti-
rCPAFIgG2aantibodies,suggestingtheinductionof arobustTh1
type response.
IMMUNIZATION OF MICE WITH BMDCs PULSED WITH rCPAF PLUS CpG
ENHANCES THE RESOLUTION OF GENITAL C. MURIDARUM INFECTION
To determine the protective immunity induced by immunization
with rCPAF-pulsed BMDCs, immunized mice were challenged
intravaginally with C. muridarum 1month after the second adop-
tive immunization. Vaginal chlamydial recovery was measured
every third day post-challenge for a period of 30days,vaccination
with DC+HEL/CpG (unrelated antigen) served as the baseline
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forthedegreeof Chlamydia shedding,whichwassimilartomock-
vaccinated mice over a 30-day period. As shown in Figure 5A,B,
vaccination with rCPAF-pulsed BMDCs induced a signiﬁcant
reduction (p <0.05) in bacterial shedding, with clearance of the
infection in 50% of the mice as early as day 15, and in all (100%)
mice by day 18 after challenge. In comparison, all of the HEL–
BMDC(mock)immunizedanimalswerestillsheddingChlamydia
on day 18 after challenge, and exhibited complete clearance on
day 30 after challenge. As expected,animals immunized with UV-
EB pulsed BMDCs began to resolve the infection as early as day
3 after challenge, and all (100%) mice in this group completely
cleared the infection by day 18 after challenge. These results sug-
gestedvaccinationwithBMDCspulsedwithrCPAF+CpGdidnot
induce resistance to infection, but mediated signiﬁcantly accel-
erated chlamydial clearance leading to complete resolution of
infection within the same time period as UV-EB pulsed BMDC
immunized animals.
IMMUNIZATION OF MICE WITH BMDCS PULSED WITH RCPAF PLUS
CPG INDUCES PROTECTION AGAINST C. MURIDARUM-INDUCED
UPPER GENITAL TRACT PATHOLOGY
To determine the effect of immunization with rCPAF-pulsed
BMDCs on development of Chlamydia-induced disease sequelae,
the development of hydrosalpinx on day 80 after challenge was
evaluated. Vaccination with BMDCs pulsed with rCPAF+CpG
reduced the development of hydrosalpinx (17% bilateral) on
FIGURE5|( A )Vaginal chlamydial shedding was measured post-challenge.
Groups (six mice per group) were immunized s.c. with BMDCs pulsed with
HEL+CpG, rCPAF+CpG, or UV-EB+CpG, and booster immunizations
were given on day 14. One month after the ﬁnal immunization, mice were
challenged i.vag. with 5×10
4 IFU of C. muridarum. Chlamydial shedding
was monitored every third day after challenge for 1month, vaccination with
DC+HEL/CpG (unrelated antigen) served as the baseline for the degree of
Chlamydia shedding, which was similar to mock-vaccinated mice over a
30-day period.The mean±SEM of chlamydial shedding per group at each
time point is shown. (∗) Signiﬁcant reductions (p <0.05; one-way ANOVA) in
bacterial shedding at the indicated time points between the indicated group
and HEL+CpG-pulsed groups are shown.The results are one experiment
from two independent experiments with similar results. (B)The number of
animals shedding Chlamydia at the respective days after genital challenge.
day 80 after chlamydial challenge compared to animals immu-
nized with BMDCs pulsed with HEL+CpG (mock immunized,
50%bilateral).BMDCspulsedwithUV-EB+CpGimmunization
induced comparable levels of protection against development of
hydrosalpinx (33% bilateral) to those pulsed with rCPAF+CpG,
following chlamydial challenge (Figure 6A).
Gross oviduct cross-sectional diameter also was measured
as a quantitative indicator of the degree of hydrosalpinx. As
shown in Figure 6B, animals immunized by BMDCs pulsed
with HEL+CpG (mock immunized) displayed a high degree
of oviduct dilatation (2±0.39mm) on day 80 after chlamy-
dial challenge. In contrast, animals vaccinated with BMDCs
pulsed with rCPAF+CpG displayed signiﬁcantly reduced dilata-
tion of oviducts (0.66±0.21mm). Animals vaccinated with
UV-EB pulsed BMDCs also displayed signiﬁcant reductions
(1.21±0.26mm) in dilatation score.
The presence of inﬂammatory cellular inﬁltrates in the gen-
ital tract tissues was scored by microscopy (Figure 6C). Mice
immunized with BMDCs pulsed with rCPAF+CpG or UV-
EB+CpGdisplayedsigniﬁcant(p ≤0.05)reductionsinmononu-
clear cells (0.92±0.25 and 1.08±0.20, respectively) and plasma
cells(0.42±0.15and0.33±0.11respectively),comparedtothose
immunized with BMDCs pulsed with HEL+CpG (mononu-
clear cells 2.1±0.25, plasma cells 1.42±0.35). These results
indicate that vaccination with BMDCs pulsed with rCPAF+CpG
FIGURE 6 |The upper genital tract pathology was measured on day 80
after challenge. (A) Percentage of mice developing hydrosalpinx in
different immunization groups after genital chlamydial challenge. (B)The
oviduct dilation after vaccination and chlamydial challenge. Groups (six mice
per group) were immunized s.c. with HEL+CpG, rCPAF+CpG, or
UV-EB+CpG on day 0, and booster immunizations were given on day 14.
One month after the ﬁnal immunization, mice were challenged i.vag. with
5×10
4 IFU of C. muridarum. On day 80 after challenge, oviduct dilatation
was measured. Each individual marker represents one oviduct, and the
mean±SEM of oviduct diameter per group of mice also is shown. (∗)
Signiﬁcant (p <0.05, chi-square test) difference in oviduct diameter
between the indicated group and HEL+CpG-pulsed group, respectively.
(C) On day 80 after challenge, inﬁltration of mononuclear cells and plasma
cells were scored.The means±SEM of the scores per group are shown. (∗)
Signiﬁcant differences (p<0.05; Kruskal–Wallis one-way ANOVA on ranks)
between the indicated groups and HEL+CpG-pulsed group are shown.
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induces robust protection against oviduct pathology and reduces
inﬂammatory cellular inﬁltration.
DISCUSSION
Dendriticcellsarecentraltoinductionof immunitytochlamydial
genital tract infection, and potent immunity against genital tract
reinfection, comparable to that induced by prior live chlamydial
infectionandhasbeenachievedinthemousemodelbyimmuniza-
tion with DCs pulsed ex vivo with whole inactivated organisms
(Su et al., 1998; Rey-Ladino et al., 2005). Thus, DC-based vac-
cination and immunotherapy provide a promising new tool for
development of an effective Chlamydia vaccine. There have been
positive efforts to improve DC-based vaccination approaches for
cancer immunotherapy in the last decade. Several clinical trials
of human DC-based vaccines are generating encouraging prelim-
inary results demonstrating that there is an induction of tumor-
speciﬁcimmuneresponsesandtumorregression(Santegoetsetal.,
2008; Le et al., 2010). These clinical DC-based vaccinations have
been proved to be feasible and safe, although continued opti-
mization is still required for broader cancer immunotherapy and
potential applications against infectious diseases.
The present study shows that BMDCs pulsed ex vivo with
rCPAF+CpG are effective in inducing optimal surface activa-
tion markers and functional maturation of DCs, including up-
regulated expression of CD86, CD80, CD40, MHC II; enhanced
production of IL-12, but not IL-10 and IL-4, and an increased
abilitytoprocessandpresentCPAFantigenstoChlamydia-speciﬁc
CD4+Tcells.Moreover,protectiveimmunityagainstgenitalinfec-
tion can be achieved by subcutaneous immunization of mice
with BMDCs pulsed ex vivo with rCPAF+CpG. These mice also
displayed complete vaginal chlamydial clearance by day 18 post-
challenge and a reduced incidence (50%) of hydrosalpinx and
histopathology, compared to clearance on day 30 and hydros-
alpinx in 83% mice in HEL+CpG-BMDCs immunized mice.
TheseresultsdemonstratethatBMDCspulsedwitharecombinant
chlamydial antigen may be used to induce robust anti-Chlamydia
protective immunity at the genital mucosa.
Subcutaneous immunization with BMDCs pulsed ex vivo with
rCPAF+CpG also induced robust antibody and cell mediated
antigen-speciﬁcTh1typeresponsesandIFN-γ production,which
resultedinthesigniﬁcantenhancementofgenitalchlamydialclear-
ance and reduction of oviduct pathology. Although DC-based
vaccines can efﬁciently present antigen to B cells and CD4+ T
cells, the activation of CD4+ T cells by DCs can exert helper
functions to enhance efﬁcient antibody production, production
of high-afﬁnity antibodies through somatic hypermutation, and
class-switchingofantibodies(TamuraandChiba,2009).However,
therewasnoevidenceof resistancetoinitialinfection,orafurther
enhancement in protective immunity compared to that induced
by intranasal vaccination with soluble rCPAF+CpG (Cong et al.,
2007) or rCPAF+IL-12 (Murthy et al., 2007)a sd e m o n s t r a t e di n
our previous published studies. These results may suggest that the
degree of priming obtained by DC vaccination and/or subsequent
activation of CD4+ T cells may be comparable to that obtained
following vaccination with soluble antigen. The lack of resistance
to initial infection conﬁrms and extends our prior ﬁndings that
anti-CPAF antibodies are not capable of neutralizing chlamydial
infectivity(Lietal.,2010).Wehypothesizethatthisresultsdirectly
from the fact that CPAF is a late-phase protein, produced only
during the RB phase, and not present in the infectious EB phase
of the chlamydial organism. Additionally, DC immunization may
induce robust antigen-speciﬁc IFN-γ responses,but did not result
insuperiorprotectiveimmunitywhencomparedtosolublerCPAF
immunization. This may suggest that cell mediated immunity is
onlycapableofinducingenhancedandcompleteclearancearound
days 15–18 after genital C. muridarum challenge. This also is
supported by clearance of infection in a similar time period fol-
lowingimmunizationwithBMDCspulsedwithinactivatedwhole
chlamydialorganisms.However,itcannotbeexcludedthatBMDC
immunization administered intravenously as in previous reports
(Su et al., 1998; He et al., 2005), instead of subcutaneously as in
this study, may have resulted in chlamydial clearance at earlier
time periods. In the previous reports, the BMDC immunization
wasdeliveredviatheretro-orbitalplexus(Suetal.,1998),amethod
that has been considered invasive and less favorable in recent
years. Given the promising potential of CPAF in inducing anti-
chlamydial protective immunity,it may be worthwhile to evaluate
intravenousimmunizationwithrCPAF-pulsedBMDCsviathetail
vein in future studies.
Collectively, BMDCs pulsed ex vivo with rCPAF plus CpG
inducedenhancementsingenitalchlamydialclearanceandreduc-
tionof oviductpathologycomparabletoourpaststudieswithsol-
uble rCPAF+CpG intranasal vaccination (Murthy et al., 2007; Li
etal.,2010).Theseresultsconﬁrmandextendourpreviousreports
on the efﬁcacy of CPAF immunization in reducing Chlamydia-
induced upper genital tract pathological sequelae. They also sug-
gest that inducing chlamydial clearance at earlier time periods
may require the inclusion of a chlamydial surface antigen,such as
native MOMP which has been shown to induce antibodies that
neutralize chlamydial infectivity (Pal et al.,2008;Kari et al.,2009),
into a combination vaccine to achieve optimal anti-chlamydial
protective immunity. Such a combination would display the ben-
eﬁt of MOMP mediated neutralizing antibody effects against
speciﬁc serovars with partial resistance to infection resulting in
reduced transmission, and cell mediated immunity induced by
CPAFagainstmultipleserovarsandspeciesofChlamydia,resulting
in reduction of oviduct pathological sequelae.
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